source
- Merck ADC, in China study, shows potential to replace chemo in lung cancerThe results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.BioPharma Dive · 15d ago↗ source
- Braveheart, Attovia join next wave of biotech IPOsThe two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.BioPharma Dive · 15d ago↗ source
- STAT+: Celcuity’s breast cancer drug approved, its firstFDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The ReadoutSTAT · 15d ago